CLAIMS

1. Use of a FGF19 variant in the manufacture of a medicament for treating a FGF19-dependent cancer or tumor, or a symptom thereof, in a subject, wherein the FGF19 variant comprises SEQ ID NO: 1.

2. Use of a FGF19 variant in the manufacture of a medicament for treating a FGF19-dependent cancer or tumor, or a symptom thereof, in a subject, wherein the FGF19 variant consists of SEQ ID NO: 1.

3. Use of a FGF19 variant in the manufacture of a medicament for preventing a FGF19-dependent cancer or tumor, or a symptom thereof, in a subject, wherein the FGF19 variant comprises SEQ ID NO: 1.

4. Use of a FGF19 variant in the manufacture of a medicament for preventing a FGF19-dependent cancer or tumor, or a symptom thereof, in a subject, wherein the FGF19 variant consists of SEQ ID NO: 1.

5. The use of the FGF19 variant of any one of claims 1 to 4, wherein FGF19 variant is fused with an immunoglobulin Fc region.

6. The use of the FGF19 variant of any one of claims 1 to 5, wherein the FGF19-dependent cancer or tumor is hepatocellular carcinoma, a colon cancer or tumor, a prostate cancer or tumor, or a lung cancer or tumor.

7. The use of the FGF19 variant of claim 6, wherein the FGF19-dependent cancer or tumor is hepatocellular carcinoma.

8. The use of the FGF19 variant of claim 6, wherein the FGF19-dependent cancer or tumor is a colon cancer or tumor.

9. The use of the FGF19 variant of claim 6, wherein the FGF19-dependent cancer or tumor is a prostate cancer or tumor.

10. The use of the FGF19 variant of claim 6, wherein the FGF19-dependent cancer or tumor is a lung cancer or tumor.